Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infection in the AVIATOR study

Clinical Infectious Diseases

Volumn 60, Issue 4, 2015, Pages 608-610

  Poordad, Fred ^a   Agarwal, Kosh ^b   Younes, Ziad ^c   Cohen, Daniel ^d   Xie, Wangang ^d   Podsadecki, Thomas ^d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c Gastro One   (United States)

^d ABBVIE INC   (United States)

Author keywords

concordance; direct acting antivirals; hepatitis C; sustained virologic response

Indexed keywords

ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; INTERFERON; MACROCYCLIC COMPOUND; RIBAVIRIN; RITONAVIR; SULFONAMIDE; URACIL; VIRUS RNA;

ADULT; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; DRUG COMBINATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; MALE; RECURRENT DISEASE; VIROLOGY; VIRUS LOAD;

ADULT; ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MACROCYCLIC COMPOUNDS; MALE; RECURRENCE; RIBAVIRIN; RITONAVIR; RNA, VIRAL; SULFONAMIDES; URACIL; VIRAL LOAD;

EID: 84922372748     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu865     Document Type: Article

References (16)

1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10:553-62
2. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17:107-15
3. Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013; 144:1450-5.e2
4. Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51:1122-6
5. Zeuzem S, Heathcote EJ, Shiffman ML, et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol 2003; 39:106-11
6. Lawitz E, Gane EJ, Lalezari J, et al. High concordance of SVR4, SVR12, and SVR24 in patients with HCV infection who have received treatment with sofosbuvir. J Hepatol 2013; 58(suppl 1):S348
7. Yoshida EM, Sulkowski MS, Gane EJ, et al. The concordance between SVR4, SVR12, and SVR24 in patients with chronic HCV infection who received treatment with sofosbuvir in phase 3 clinical trials. Hepatology 2013; 58(suppl 1):138A
8. Zeuzem S, Mensa FJ. Concordance between sustained virologic response week 12 (SVR12) and SVR24 in genotype 1 hepatitis C virus patients receiving interferon-free treatment in the SOUND-C2 study. Hepatology 2013; 58:1516
9. Zeuzem S, Soriano V, Asselah T, et al. SOUND-C2: SVR4, 12, and 24 concordance in genotype (GT) 1 HCV patients receiving interferon (IFN)-free treatment with the HCV NS3/4A protease inhibitor BI 201335 and the NS5B polymerase inhibitor BI 207127. Hepatology 2012; 56(suppl 1):569A
10. Leof A, Gerrity M, Thielke A, King V. Sofosbuvir for the treatment of hepatitis C and evaluation of the 2014 American Association for the Study of Liver Diseases treatment guidelines. Portland: Center for Evidence-based Policy, Oregon Health & Science University, 2014
11. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl JMed 2014; 370:222-32
12. Kwiecien R, Kopp-Schneider A, Blettner M. Concordance analysis: part 16 of a series on evaluation of scientific publications. Dtsch Arztebl Int 2011; 108:515-21
13. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52:889-900
14. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384:403-13
15. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, doubleblind, placebo-controlled phase 3 trial. Lancet 2014; 384:414-26
16. Olysio (simeprevir) [package insert]. Titusville, NJ: Janssen Therapeutics, 2013